Background. Endothelin-1 (ET-1) is the most powerful factor known to release atrial natriuretic peptide (ANP) in vivo and in cultured cardiac myocytes or preparations of atrium. We tested the role of endogenous ET-1 in the regulation of ANP release by passive immunization in anesthetized rats.
A trial natriuretic peptide (ANP) is released from atrial myocytes in response to increased atrial filling pressure and atrial wall distension.1-3 The mechanism whereby atrial wall stretch distension causes ANP release is unknown. Several vasoactive hormones, including epinephrine,4 norepinephrine,5 calcitonin gene-related peptide (CGRP),6 endothelin-1 (ET-1), 7, 8 and vasopressin,9 reportedly stimulate ANP release in vitro or in vivo. Whether these hormones are physiological regulators of ANP release is currently unknown. Cellular influx of calcium appears to play a role, since calcium ionophores stimulate and calcium entry blockers decrease ANP release. 2 ET-1, a 21-amino acid peptide produced by endothelial cells,10 is a potent secretagogue for ANP release in cultured atrial myocytes, in the isolated rat heart preparation, and in the intact animal. ET-1 production in endothelial cells is increased by fluid dynamic shear stress,11 transforming growth factor-3,12 thrombin,10 an-giotensin 11,13 vasopressin,13 and insulin.14 The effect of ET-1 on ANP release has been studied only by application of synthetic polypeptide. To test whether endogenous endothelin modulates ANP release in vivo, we treated Wistar rats with rabbit antiserum to ET-1. We observed that such treatment attenuated volume-stimulated ANP release and lowered basal plasma ANP levels.
Methods

Experimental Animals
Male Wistar rats weighing 265 to 400 g were used. Rats Plasma ANP After Acute Volume Load
Rats pretreated with 0.1 mL IV of endothelin antiserum showed a markedly attenuated response to acute volume load achieved by rapid infusion of 8.0 mL of 0.9% NaCl (Fig 2) 
Antagonism of the Cardiovascular Effect of ET-I by Antiserum
Intravenous bolus injection of endothelin antiserum, 0.1 mL, exerted no significant effect on mean arterial pressure or heart rate (Fig 3) . After a brief hypotensive response, ET-1, 0.5 nmol/kg IV, increased mean arterial pressure by about 10 mm Hg (maximum, 14+4 mm Hg) for the entire observation period of 50 minutes while, concomitantly, the heart rate was decreased (maximum, 34±4 beats per minute; Fig 4, A and B) . Pretreatment with ET-1 antiserum did not modify the initial hypotensive response to ET-1 but significantly decreased the magnitude and duration of the hypertensive response. Bradycardia induced by the ET-1 bolus was not significantly modified by the antiserum pretreatment.
Discussion
Immunological inhibition of endogenous endothelin was shown here to reduce basal plasma ANP levels in anesthetized rats. Moreover, endothelin antiserum clearly attenuated the increase of plasma ANP originally shown to occur in response to acute volume load.' These observations strongly suggest that endothelin plays a modulatory role in the regulation of both basal and stimulated ANP secretion.
Our findings accord with reported stimulation by synthetic ET-1 of ANP release from superfused rat atria. 19 Both basal and stretch-induced ANP release was stimulated by ET-1 in perfused rat heart preparation.20
Moreover, endothelin-induced release of ANP was shown in a coculture of bovine endothelial cells and rat atrial myocytes.2' ET-1 infusion or intravenous bolus injection22 caused increase of plasma ANP concentrations in rats. However, these observations do not justify definite conclusions regarding the possible role of endogenous endothelin in ANP regulation. The close vicinity of ET-1 producing cells to atrial myocytes in atrial endothelium and the abundance of ET-1 receptors in atrial myocytes23 lends further support to the concept that endothelin may modulate ANP release. ANP is released into the circulation from atrial myocytic storage granules in response to atrial distension.'-3 The exact mechanism whereby ANP release is brought about has not been clarified.
Endothelin causes rapid influx of extracellular calcium into myocytes.10 This may mediate ANP release from storage granules. In fact, calcium ionophores increase ANP release from myocytes, and calcium channel blockers do the opposite.2 Accordingly, endothelininduced ANP release from rat atria was inhibited in part by verapamil, a calcium channel blocker.7
In comparison with other hormones causing ANP release, ET-1 appears to be the most powerful one on a molar basis. CGRP, which is present in the atrial wall, is almost as potent as ET-1 in this regard.6 Less potent but also capable of releasing ANP are angiotensin II, epinephrine, and norepinephrine. Vasopressin was recently shown to restore volume-stimulated ANP release in pithed rats. 24 Thus, ANP release may be modulated by permissive or facilitating effects of several vasoactive hormones, including ET-1, CGRP, and vasopressin. A weakness of using ET-1 antiserum is that blockade of ET-1 is incomplete, since only about 90% or even less of the administered ET-1 bolus dose may be bound by the antibodies administered (unpublished data from our laboratory). This may explain why endothelin antiserum only partly inhibited stimulated ANP release and the blood pressure-raising effect of synthetic endothelin. The initial lowering of blood pressure after intravenous ET-1, thought to be caused by rapid release of nitric oxide from vascular endothelial cells,26 was not inhibited by endothelin antiserum. This may be explained by a difference between endothelin receptors in endothelial cells and those in myocytes. In fact, endothelial cells reportedly carry nonspecific endothelin receptors of endothelin B-type, which bind endothelins 1 through 3,27 whereas myocytes have endothelin A-type receptors specific for ET-1. It is of note that inhibition of ET-1 pressor responses by the endothelin A-type receptor antagonist FR 139317 in the rat was nearly complete, but the initial blood pressure reduction was not affected. 28 Moreover, blood ET-1 concentrations after administration of endothelin (5 nmol/kg body weight) may have been too high to allow effective immunological blockade at the level of the endothelium.
Endothelin antiserum may also block ANP release recently shown to be mediated by carotid-aortic baroreceptors.29 These investigators29 pointed out that ET-1 is found in the hypothalamus and neuronal terminals of the neurohypohysis30 and may, after its release into the circulation, stimulate ANP release.7 '8 Because endothelin antiserum affected neither blood pressure nor heart rate, the decrease of basal and stimulated plasma ANP concentration could not have been brought about by hemodynamic effects of the antiserum bolus injection.
In conclusion, we have shown that passive immunization with endothelin antiserum decreases basal plasma ANP concentrations and volume-stimulated increase of plasma ANP, suggesting an important modulatory role for endothelin in the regulation of ANP release.
